Evommune IPO: revenue, losses and offering terms from its S-1
Evommune priced its IPO at $16 a share on 6 Nov 2025 and raised $150 million. Its shares trade on NYSE as EVMN. Revenue was $7.0 million in 2024, up 40% from 2023, with a net loss of $66.8 million.
Headlines
- Revenue, 2024
- $7M
- Up 40% on the year before
- Net loss, 2024
- $67M
- Revenue, First half of 2025
- $3M
- Down 57% on a year earlier
- IPO price
- $16
- $150M raised
Evommune IPO terms
From the final prospectus (424B4).
- Exchange
- New York Stock Exchange
- Ticker
- EVMN
- IPO price
- $16
- Shares offered
- 9,375,000
- Raised
- $150M
- Registered
- $118M, the amount the filing fee is paid on
- Underwriters
- Morgan Stanley, Leerink Partners, Evercore ISI and Cantor
- First filed
- 9 Oct 2025
Evommune revenue and profit
| Period | Revenue | Operating income | Net income |
|---|---|---|---|
| 2023 | $5M | - | -$34M |
| 2024 | $7M | -$70M | -$67M |
| First half of 2024 | $7M | - | - |
| First half of 2025 | $3M | -$38M | -$28M |
Evommune share structure and company facts
- Employees
- 45
- Headquarters
- Palo Alto, CA
Evommune shares since the IPO
Latest close 26 Oct 2026
- IPO price
- $16
- Priced 6 Nov 2025
- First close
- $20.23
- +26% on the IPO price
- Latest close
- $5.13
- -68% on the IPO price
Evommune's IPO filings
The registration statement, each amendment and the final prospectus, oldest first.
About the data
- Terms and financials are read from Evommune's newest prospectus (424B4 filed 6 Nov 2025) by a Kadoa workflow. Check figures that matter against the filing.
- Registered is the amount the filing fee is paid on, often a placeholder before the price range is set.
- Raised is the IPO price times the shares sold, without the underwriters' option. Trading compares the first and latest close with the IPO price.